Diffuse large B-cell lymphoma
Conditions
Interventions
Observation group:N/A
Sponsors
Sun Yat-sen University Cancer Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Histologically confirmed CD20-positive, previously untreated diffuse large B-cell lymphoma, not otherwise specified (DLBCL-NOS); 2.Received first-line treatment with either the Hi-CHOP regimen (Zercepac 375 mg/m^2 + CHOP, q3w, >= 3 cycles) or the R-CHOP regimen (Rituximab 375 mg/m^2 + CHOP, q3w, >= 3 cycles). 3.Age and gender are not restricted. 4.Complete survival follow-up and adequate data availability can be achieved prior to study initiation.
Exclusion criteria
Exclusion criteria: 1.Key data on demographic information and medication information are missing. 2.Survival data are missing or the patient refused survival follow-up. 3.The investigator determined that other ineligible conditions exist (e.g., concomitant other malignancies, non-standard treatment regimens, etc.).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 5-year Overall Survival (OS) Rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| 5-year progression-free survival (PFS) rate;Secondary Endpoint;4-year Progression-Free Survival (PFS) Rate; | — |
Countries
China
Contacts
Public ContactLi Zhiming
Sun Yat-sen University Cancer Center
Outcome results
None listed